Synonyms: CM-082 | CM082 | Example 8 [WO2008033562A2] | EYP-1901 | X-82
Compound class:
Synthetic organic
Comment: Vorolanib (CM082) is a potent and selective, oral clinical stage multi-kinase inhibitor. Targets include all VEGFR isoforms, PDGFR and CSF1R. [1-3]. It is a structural derivative of sunitinib. Vorolanib has anti-angiogenic activity, and is being investigated for anti-tumour effects and utility to treat ocular neovascularisation.
|
|
References |
1. Dan H, Lei X, Huang X, Ma N, Xing Y, Shen Y. (2021)
CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo. Microvasc Res, 136: 104146. [PMID:33610563] |
2. Liang C, Gao S, Li X. (2008)
Kinase inhibitor compounds. Patent number: WO2008033562A2. Assignee: Xcovery, Inc.. Priority date: 15/09/2006. Publication date: 20/03/2008. |
3. Ren C, Shi H, Jiang J, Liu Q, Du Y, He M, Cai W, Wei Q, Yu J. (2017)
The Effect of CM082, an Oral Tyrosine Kinase Inhibitor, on Experimental Choroidal Neovascularization in Rats. J Ophthalmol, 2017: 6145651. [PMID:29201457] |
4. Sheng X, Yan X, Chi Z, Cui C, Si L, Tang B, Li S, Mao L, Lian B, Wang X et al.. (2020)
Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine, 55: 102755. [PMID:32335374] |
5. Song Y, Wang J, Ren X, Jin J, Mao L, Liang C, Ding L, Yang L. (2021)
Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res, 33 (1): 103-114. [PMID:33707933] |